Catalog No.: PC-73419Not For Human Use, Lab Use Only.
Garsorasib (D-1553) is a potent, selective, orally bioavailable and covalent KRas-G12C inhibitor with IC50 of 10 nM, exhibits potent anti-tumor activity in a broad spectrum of tumor cell lines.
Garsorasib (D-1553) is a potent, selective, orally bioavailable and covalent KRas-G12C inhibitor with IC50 of 10 nM, exhibits potent anti-tumor activity in a broad spectrum of tumor cell lines.
Garsorasib (D-1553) shows specific activity in cancer cells with KRas-G12C mutation, including lung, pancreatic and colorectal cancers.
Garsorasib (D-1553) is highly potent in vivo in various cell line-derived xenograft tumor models with KRas-G12C mutation as a single agent.
Garsorasib (D-1553) demonstrates further tumor growth inhibition or regression in tumor xenograft models, when combined with MEK inhibitor, SHP2 inhibitor or cytotoxic agents.
Garsorasib (D-1553) has anti-tumor activity in a broad spectrum of cancers and is suitable for tissue-agnostic clinical development targeting cancers with KRas-G12C mutation.
